July 30, 2013
Meiji Seika Pharma announced on July 26 that the company has initiated a PI study of the arbekacin inhalation solution (development code: ME1100) in the US for the treatment of hospital acquired bacterial pneumonia (HABP) and ventilator associated bacterial pneumonia...read more